Cardiff Oncology, Inc.
CRDF
$2.13
$0.094.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -0.83% | 11.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.83% | 11.01% | |||
| Cost of Revenue | -29.21% | 10.53% | |||
| Gross Profit | 29.51% | -10.52% | |||
| SG&A Expenses | 17.45% | -17.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.82% | 2.81% | |||
| Operating Income | 18.97% | -2.75% | |||
| Income Before Tax | 19.26% | -3.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 19.26% | -3.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.26% | -3.79% | |||
| EBIT | 18.97% | -2.75% | |||
| EBITDA | 19.06% | -2.76% | |||
| EPS Basic | 19.69% | -3.81% | |||
| Normalized Basic EPS | 19.69% | -3.80% | |||
| EPS Diluted | 19.69% | -3.81% | |||
| Normalized Diluted EPS | 19.69% | -3.80% | |||
| Average Basic Shares Outstanding | 0.53% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.53% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||